nach oben

Current HIV/AIDS Reports

Erschienen in:

01.09.2011

Vitamin D in HIV-Infected Patients

verfasst von: Jordan E. Lake, John S. Adams

Erschienen in: Current HIV/AIDS Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Observational studies have noted very high rates of low 25(OH)D (vitamin D) levels in both the general and HIV-infected populations. In HIV-infected patients, low 25(OH)D levels are likely a combination of both traditional risk factors and HIV-specific and antiretroviral therapy–specific contributors. Because of this unique risk profile, HIV-infected persons may be at greater risk for low 25(OH)D levels and frank deficiency and/or may respond to standard repletion regimens differently than HIV-uninfected patients. Currently, the optimal repletion and maintenance dosing regimens for HIV-infected patients remain unknown, as do potential benefits of supplementation that may be unique to the HIV-infected population. This paper reviews data published on HIV infection and vitamin D health in adults over the last year.

Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2):471–8.PubMedCrossRef

Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–37.PubMedCrossRef

Ginde AA, Scragg R, Schwartz RS, Camargo Jr CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57(9):1595–603.PubMedCrossRef

Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1):4–8.PubMedCrossRef

Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes. 2008;57(10):2619–25.PubMedCrossRef

Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2813–8.PubMedCrossRef

Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2009.

Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler. 2009;15(6):735–40.PubMedCrossRef

Medicine Io. Dietary reference intakes for calcium and vitamin D. [Brief Report]. 2010 November 2010.

10.

Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5 Pt 1):226–33.PubMedCrossRef

11.

Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169(4):889–93.PubMedCrossRef

12.

Holick MF. Vitamin D: a D-Lightful health perspective. Nutr Rev. 2008;66(10 Suppl 2):S182–94.PubMedCrossRef

13.

• Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194–200. This article provides an informative review of the antiviral and immunomodulatory effects of vitamin D. PubMedCrossRef

14.

Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29(12):664–73.PubMedCrossRef

15.

Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005;35(5):290–304.PubMedCrossRef

16.

Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48(7):1247–57.PubMedCrossRef

17.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.PubMedCrossRef

18.

Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.PubMedCrossRef

19.

Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248–54.PubMedCrossRef

20.

Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662–87.PubMedCrossRef

21.

Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 Suppl):1704S–8S.PubMed

22.

Rausch-Fan X, Leutmezer F, Willheim M, Spittler A, Bohle B, Ebner C, et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol. 2002;128(1):33–41.PubMedCrossRef

23.

Girasole G, Wang JM, Pedrazzoni M, Pioli G, Balotta C, Passeri M, et al. Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol. 1990;145(8):2459–64.PubMed

24.

Orikasa M, Kawase T, Suzuki A. Induction of macrophagic and granulocytic differentiation of murine bone marrow progenitor cells by 1,25-dihydroxyvitamin D3. Calcif Tissue Int. 1993;53(3):193–200.PubMedCrossRef

25.

Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803–11.PubMedCrossRef

26.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.PubMedCrossRef

27.

Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182(7):4289–95.PubMedCrossRef

28.

Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5(4):410–5.PubMedCrossRef

29.

Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, Lehnhardt M, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2005;2:2.PubMedCrossRef

30.

Hong P, Corcoran K, Modlin R, Lee B, Krutzik S. HIV-1 ssRNA triggers a vitamin D-dependent antiviral pathway in human monocytes. 15th Conference on Retroviruses and Opportunistic Infections Boston, Massachusetts. 2008 February 2008.

31.

Conesa-Botella A, Mathieu C, Colebunders R, Moreno-Reyes R, van Etten E, Lynen L, et al. Is vitamin D deficiency involved in the immune reconstruction inflammatory syndrome. AIDS Res Ther. 2009;6(4):1–5.

32.

Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24(11):1375–82.PubMedCrossRef

33.

Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006;25(4):537–9.PubMedCrossRef

34.

Rodriguez M, Daniels B, Gunawardene S, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9–14.PubMedCrossRef

35.

Wasserman P, Rubin DS. Highly prevelent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS. 2010;24(4):223–7.PubMedCrossRef

36.

Bang UC, Shakar SA, Hitz MF, Jespersen MS, Andersen O, Nielsen SD, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis. 2010;42:306–10.PubMedCrossRef

37.

Ahmed S, Zinkiewicz P, Ninivaggi M, Verley J, Yasmin T, Khan I, Feleke G, et al. Prevalence of vitamin D deficiency in HIV population: an analysis of NHANES. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 2010.

38.

Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res. 2006;66(5):211–5.PubMedCrossRef

39.

Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196–9.PubMedCrossRef

40.

Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):396–405.PubMedCrossRef

41.

Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7(40):1–6.

42.

Mehta S, Giovannucci EL, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5(1):1–7.CrossRef

43.

Borderi M, Vescini F, Cozzi-Lepri A, Di Caro A, Shlacht I, Cassola G, et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort. 17th conference on retroviruses and opportunistic infections San Francisco, California. [Abstract]. 2010 February 2010.

44.

Adeyemi OM, Agniel D, French A, Weber K, Tien PC, Glesby M, et al. High rates of vitamin D deficiency among HIV-infected and at-risk women in the United States. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.

45.

Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008;93(1):216–24.PubMedCrossRef

46.

Brown TT, Xu X, John M, Singh J, Kingsley LA, Palella FJ, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8.PubMedCrossRef

47.

Boodram B, Plankey MW, Cox C, Tien PC, Cohen MH, Anastos K, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS. 2009;23(12):1009–16.PubMedCrossRef

48.

Haug CJ, Aukrust P, Haug E, Morkrid L, Muller F, Froland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3832–8.PubMedCrossRef

49.

Hanevold CD, Yamaguchi DT, Jordan SC. Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells. J Bone Miner Res. 1993;8(10):1191–200.PubMedCrossRef

50.

Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–20.PubMedCrossRef

51.

Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009;75(6):1392–9.PubMedCrossRef

52.

Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;44(11):1273–81.PubMedCrossRef

53.

Gyllensten K, Josephson F, Lidman K, Saaf M. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006;20(14):1906–7.PubMedCrossRef

54.

Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46(4):221–7.PubMedCrossRef

55.

de Luis DA, Bachiller P, Aller R, de Luis J, Izaola O, Terroba MC, et al. Relation among micronutrient intakes with CD4 count in HIV infected patients. Nutr Hosp. 2002;17(6):285–9.PubMed

56.

Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High Prevalence of Severe Vitamin D Deficiency in Combined Antiretroviral Therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8):112701134.CrossRef

57.

Crutchley R, Crutchley R Jr. Risk factors for vitamin D deficiency in HIV. Risk factors for vitamin D deficiency in HIV-1 infected adults in the South-Central United States Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.

58.

Gandhi V, Kim JH, Psevdos G Jr, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels in HIV-infected patients at the Center of Comprehensive Care, St Luke´s Roosevelt Hospital Center, New York, USA. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.

59.

Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, et al. Vitamin D deficiency in HIV-infected Postmenopausal Hispanic and African-American Women. Osteoporos Int. 2010;10:1–11.

60.

Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24(12):1923–8.PubMedCrossRef

61.

Allavena C. Delpierre C, Rey D, Cuzin L, Duvivier C, Viget N, et al. Effects of ARV on vitamin D concentration in HIV-infected patients: a large prospective cohort analysis. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2–11 February 27-March 2, 2011.

62.

Ross A, Judd SE, Hileman C, Labbato D, Storer N, Tangpricha V, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-infected individuals. Antivir Ther. in press.

63.

Mehta S, Spiegelman D, Magusi F, Giovanucci E, Msmanga G, Fawzi W. Vitamin D HIV-related complications and HIV disease progression in women in Tanzania. Program and abstracts of the 17th Conference on Retroviruses and Opportuistic Infections (San Francisco, CA). [Abstract]. 2010.

64.

Childs K, Fishman S, Factor S, Dieterich D, Mullen M, Branch A. First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplement. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.

65.

Havens P, Hazra R, Stephensen C, van Loan M, Rutledge B, Bethel J, et al. Vitamin D3 supplementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: a randomized, double-blind, placebo-controlled multicenter trial: Adolescent Trials Network Study 063. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.

66.

Longenecker C, Hileman C, Carman C, Ross A, Tangpricha V, Seydafkan S, et al. Vitamin D supplementation and endothelial function among vitamin D-deficient HIV-infected persons: a randomized placebo-controlled trial Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.

67.

Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–9.PubMedCrossRef

68.

Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in Vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses. 2010;26(11):1–6.

69.

Lattuada E, Lanzafame M, Zoppini G, Concia E, Vento S. No influence of nevirapine on Vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses. 2009;25(8):849–50.PubMedCrossRef

70.

Wohl D, Doroana M, Orkin C, Pilotto JH, Sungkanuparph S, Yeni P, et al. Change in vitamin D levels smaller and risk of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive, adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.

71.

Portale AA, Halloran BP, Morris Jr RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989;83(5):1494–9.PubMedCrossRef

72.

Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19(17):2031–3.PubMedCrossRef

73.

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689–96.PubMedCrossRef

74.

• Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26(8):855–9. This manuscript details a well-performed, cross-sectional, observational study, highlighting the independent associations of 25(OH)D and tenofovir use with PTH in HIV-infected patients on ART. PubMedCrossRef

75.

Pocaterra D, Ricci E, Carenzi L, Schiavini M, Meraviglia P, Minisci D, et al. Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients. Abstracts from the 18th International AIDS Conference Vienna, Austria. 2010 July 21, 2010.

76.

Gilead. Viread (tenofovir disoproxil fumarate) package insert. 2010.

77.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.PubMedCrossRef

78.

Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298–308.PubMedCrossRef

79.

Fux C, Hasse B, Opravil M, Cavassini M, Calmy A, Gurtner-delaFuente V, et al. Bone turnover, and in particular osteoclast activity, is increased in patients with confirmed proximal renal tubulopathy within the Swiss HIV Cohort Study. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.

80.

Wirz S, Rubeli S, Christen A, Popp A, Largiadèr C, Mueller N, et al. Renal phosphate wasting and increased bone turnover in tenofovir-treated patients are not mediated by low 25(OH) Vitamin D or hyperparathyroidism. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.

81.

Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54(5):496–9.PubMedCrossRef

82.

Labarga P, Barreiro P, Martin-Carbonero L, Alvarez E, Solera C, Pinilla J, et al. Prevalence and mechanisms of hyperparathyroidism in HIV+ patiens treated with TDF. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 Februrary 27-March 2, 2011.

83.

Paul TV, Asha HS, Thomas N, Seshadri MS, Rupali P, Abraham OC, et al. Hypovitaminosis D and bone mineral density in HIV infected Indian men with or without antiretroviral therapy. Endocr Pract. 2010;16(4):547–53.PubMedCrossRef

84.

Marco Borderi FV, Cozzi-Lepri A, Di Caro A, Shlacht I, Cassola G, Pellizzer G, et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian Cohort. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.

85.

Rachid T, Devitt E, Meyron I, Mandalia S, Waters L, Bower M, et al. No association of vitamin D levels with individual antiretroviral agents, duration of HIVinfection, alkaline phosphatase levels nor bone mineral density findings. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.

86.

Campbell G, Stephen S. 1,25-dihydroxycholecalciferol triggers autophagy in human macrophages that inhibits productive HIV-1 Iinfection. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.

87.

Campbell G, Stephen S. Vitamin D3 triggers autophagy in human macrophages that inhibits productive HIV-1/TB co-infection. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.

88.

Szep Z, Guaraldi G, Shah SS, Lo Re V 3rd, Ratcliffe SJ, Orlando G, et al. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS. 2011;25(00).

89.

Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Stentarelli C, et al. Vitamin D3 supplementation decreases the risk of diabetes mellitus among patients with HIV infection. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.

90.

Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27(3):181–8.PubMedCrossRef

91.

Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47(4):383–91.PubMedCrossRef

92.

Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209(4458):823–5.PubMedCrossRef

93.

Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119(1):84–90.PubMedCrossRef

94.

Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology. 1983;113(4):1511–8.PubMedCrossRef

95.

Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74.PubMedCrossRef

96.

Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr. 2010;53(2):202–8.PubMedCrossRef

97.

Shahar E, Hassoun G, Kedem E, Pollack S. Low vitamin D levels and bone density changes in young HIV+ Israeli women Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.

98.

Choi AI, Lo JC, Mulligan K, Schnell A, Kalapus SC, Li Y, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis. 2011;52(7):941–4.PubMedCrossRef

99.

Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ. 2010;182(12):E610–8.PubMedCrossRef

Titel: Vitamin D in HIV-Infected Patients
verfasst von: Jordan E. Lake
John S. Adams
Publikationsdatum: 01.09.2011
Verlag: Current Science Inc.
Erschienen in: Current HIV/AIDS Reports / Ausgabe 3/2011
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-011-0082-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Adding Fuel to the Fire: Alcohol’s Effect on the HIV Epidemic in Sub-Saharan Africa

Cardiovascular Complications in Children with HIV Infection

Cancer Screening in Patients Infected with HIV

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

Renal Issues in HIV Infection